First Cell-Derived Flu Vaccine Reaches Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Protein Sciences' seasonal influenza vaccine FluBlok has typical immunity data but some manufacturing issues.
You may also be interested in...
Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee
Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee
Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok
Cell-based seasonal influenza vaccine needs both additional safety data in general and considerably more efficacy data in older patients, FDA advisory panel says.